This change is presumably due to the preferential binding of the anti-PD-1 arm to PD-1, which is expressed in the tumour microenvironment and thus provides a sink to restrain IBI319 activity locally and avoid IBI319 systematic circulation, which may cause CD137 expression and activation in the liver. The gene discussed is PDCD1; the disease is neoplasm.